Clinical Trials Using Allogeneic Tumor Cell Vaccine

Clinical trials are research studies that involve people. The clinical trials on this list are studying Allogeneic Tumor Cell Vaccine. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-4 of 4
  • Lenalidomide with or without an Allogeneic Myeloma Vaccine and Prevnar-13 in Treating Patients with Newly Diagnosed, Recurrent, or Refractory Multiple Myeloma

    This phase II trial studies how well lenalidomide with or without an allogeneic myeloma vaccine and prevnar-13 work in treating patients with multiple myeloma that is newly diagnosed, does not respond to treatment (refractory), or has come back (recurrent). Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vaccines, such as an allogeneic myeloma vaccine and prevnar-13, may help the body build an effective immune response to kill cancer cells. Giving lenalidomide with an allogeneic myeloma vaccine and prevnar-13 may work better than lenalidomide alone in treating patients with multiple myeloma.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Vaccine Therapy and Cyclophosphamide in Treating Patients with Pancreatic Cancer

    This phase II trial studies the side effects and how well vaccine therapy and cyclophosphamide work in treating patients with pancreatic cancer. Vaccines may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide may also stimulate the immune system in different ways and stop tumor cells from growing. Giving vaccine therapy together with cyclophosphamide may be an effective treatment for pancreatic cancer.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Cyclophosphamide and Vaccine Therapy with or without Trastuzumab in Treating Patients with Stage IV Breast Cancer

    This trial studies cyclophosphamide and vaccine therapy with or without trastuzumab in treating patients with stage IV breast cancer. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vaccines made from gene-modified tumor cells may help the body build an effective immune response to kill tumor cells. Immunotherapy with trastuzumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether cyclophosphamide and vaccine therapy is more effective when given together with or without trastuzumab in treating patients with breast cancer.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Combination Study of SV-BR-1-GM in Combination With INCMGA00012 and Epacadostat

    This is an open-label study of Study WRI-GEV-007, which evaluates SV-BR-1-GM in metastatic or locally recurrent breast cancer patients, in combination with the PD-1 inhibitor INCMGA00012 and the IDO inhibitor epacadostat. Patients who with advanced breast cancer who have failed prior therapies will be eligible to enroll in this study. The study will evaluate SV-BR-1-GM in combination with INCMGA00012 and epacadostat. Treatment cycles will be every 3 weeks with evaluations for tumor progression or response every 6-12 weeks.
    Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida